-
Review Meta Analysis
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
- Omar Abdel-Rahman, Hesham ElHalawani, and Mona Fouad.
- Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Future Oncol. 2016 Feb 1; 12 (3): 413-25.
BackgroundWe performed a meta-analysis of the risk of endocrine adverse events associated with immune check point inhibitors.MethodsEligible studies included randomized trials of cancer patients on immune checkpoint inhibitors; describing events of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency.ResultsA total of ten clinical trials were eligible for the meta-analysis. The relative risk of all-grade hypothyroidism, hyperthyroidism, hypophyisitis and adrenal insufficiency were 8.26 (95% CI: 4.67-14.62; p < 0.00001), 5.48 (95% CI: 1.33-22.53; p = 0.02); 22.03 (95% CI: 8.52-56.94; p < 0.00001), 3.87 (95% CI: 1.12-13.41; p = 0.03), respectively.ConclusionOur meta-analysis has demonstrated that the use of immune check point inhibitors is associated with an increased risk of hypothyroidism, hyperthyroidism, hypophysitis and adrenal insufficiency compared with control.
Notes
Knowledge, pearl, summary or comment to share?